Baijin Life Science Holdings Limited (Baijin Life Science) has released its Monthly Return for the period ended 30 April 2026, confirming stability in its share capital while implementing a sizeable grant of new share options.

Key Highlights

1. Share Capital and Public Float • Authorised share capital remained unchanged at 10.00 billion ordinary shares with a par value of HKD0.02 each, representing HKD200.00 million in authorised capital. • Issued share capital was steady at 932.25 million ordinary shares. The company held no treasury shares at month-end. • Baijin Life Science confirmed full compliance with the Main Board’s minimum public float requirement of 25%.

2. Equity Incentives • Under the Share Option Scheme adopted on 30 September 2024, the company granted 67.93 million new share options during April 2026. • No options were exercised in the period; consequently, there were no new shares issued and no treasury shares transferred. • The newly granted options equate to approximately 7.29% of the company’s existing issued share base, increasing total outstanding options under the scheme to 67.93 million. • No warrants, convertible securities, or other share-issuance agreements were reported for the month.

3. Capital Structure Overview (as at 30 April 2026) • Authorised share capital: HKD200.00 million (10.00 billion shares). • Issued shares: 932.25 million, unchanged month-on-month. • Treasury shares: none.

The company stated that all corporate actions undertaken in April complied with Hong Kong Stock Exchange listing rules and relevant legal requirements, and that all funds due from any securities transactions have been duly received.